Physician profile
Wei Rao
NPI 1245676360
$18,614.52
in general payments reported to CMS, 2019-2025
37 companies · $2,775 in 2025
The $2,775 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $2,345 · 2021: $3,466 · 2022: $3,169 · 2023: $3,105 · 2024: $2,957 · 2025: $2,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,825 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,824.94 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,458.47 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,940.48 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Lilly USA, LLC | $1,665.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,458.95 | 2019-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $1,267.86 | 2021-2025 | |
| Novo Nordisk INC | $1,250.30 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Biotech, INC. | $1,146.25 | 2022-2025 | Tremfya |
| Pfizer INC. | $1,028.93 | 2020-2025 | |
| Gilead Sciences, INC. | $889.90 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $812.84 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbvie INC. | $752.94 | 2021-2025 | |
| Amarin Pharma, INC. | $635.94 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $614.44 | 2019-2025 | Farxiga, Airsupra, Andexxa |
| Esperion Therapeutics, INC. | $415.25 | 2020-2024 | Nexletol |
| Radius Health, INC. | $409.27 | 2019-2025 | Tymlos |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.